OBJECTIVE: To evaluate the use of levodopa therapy in patients with Parkinson's disease and malignant melanoma. DATA SOURCES: A MEDLINE search (January 1966-September 1999) of English-language articles was conducted. Key search terms included levodopa, melanoma, and Parkinson's disease; 34 case reports were identified. DATA SYNTHESIS: Carbidopa/levodopa continues to be a mainstay in the treatment of Parkinson's disease. Since the late 1970s, a warning has appeared in the prescribing literature for levodopa regarding the risk of activating malignant melanoma. An evaluation was conducted of the case reports in which a causal relationship between levodopa and melanoma was suggested. CONCLUSIONS: There is an unlikely association between levodopa and induction or exacerbation of malignant melanoma.
OBJECTIVE: To evaluate the use of levodopa therapy in patients with Parkinson's disease and malignant melanoma. DATA SOURCES: A MEDLINE search (January 1966-September 1999) of English-language articles was conducted. Key search terms included levodopa, melanoma, and Parkinson's disease; 34 case reports were identified. DATA SYNTHESIS: Carbidopa/levodopa continues to be a mainstay in the treatment of Parkinson's disease. Since the late 1970s, a warning has appeared in the prescribing literature for levodopa regarding the risk of activating malignant melanoma. An evaluation was conducted of the case reports in which a causal relationship between levodopa and melanoma was suggested. CONCLUSIONS: There is an unlikely association between levodopa and induction or exacerbation of malignant melanoma.
Authors: Manfred Hauben; Lester Reich; Eugène P Van Puijenbroek; Charles M Gerrits; Vaishali K Patadia Journal: Eur J Clin Pharmacol Date: 2006-08-03 Impact factor: 2.953
Authors: R Inzelberg; J M Rabey; E Melamed; R Djaldetti; A Reches; S Badarny; S Hassin-Baer; O Cohen; H Trau; J Aharon-Peretz; R Milo; M Schwartz; M Huberman; L Gilead; M Barchana; I Liphshiz; C Fitzer-Attas; N Giladi Journal: J Neural Transm (Vienna) Date: 2011-02-05 Impact factor: 3.575